- Home
- YORW vs RAPT Comparison
YORW vs RAPT Comparison
Compare YORW & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | YORW | RAPT |
|---|---|---|
| Founded | 1816 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.0M | 498.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | YORW | RAPT |
|---|---|---|
| Price | $33.14 | $57.66 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $56.22 |
| AVG Volume (30 Days) | 58.6K | ★ 2.1M |
| Earning Date | 03-03-2026 | 03-05-2026 |
| Dividend Yield | ★ 2.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.39 | N/A |
| Revenue | ★ $76,882,000.00 | N/A |
| Revenue This Year | $6.14 | N/A |
| Revenue Next Year | $7.69 | N/A |
| P/E Ratio | $23.87 | ★ N/A |
| Revenue Growth | ★ 3.63 | N/A |
| 52 Week Low | $29.68 | $5.67 |
| 52 Week High | $36.48 | $57.71 |
Technical Indicators
Market Signals| Indicator | YORW | RAPT |
|---|---|---|
| Relative Strength Index (RSI) | 52.85 | 80.08 |
| Support Level | $33.19 | $32.00 |
| Resistance Level | $34.09 | $57.71 |
| Average True Range (ATR) | 0.63 | 1.63 |
| MACD | 0.11 | 2.90 |
| Stochastic Oscillator | 65.62 | 99.75 |
Price Performance
Historical ComparisonAbout YORW York Water Company (The)
The York Water Co is an investor-owned water utility company in the United States. The primary business of the company is to impound, purify to meet or exceed safe drinking water standards and distribute water. It also owns and operates three wastewater collection systems and eleven wastewater collection and treatment systems. The company operates within its franchised territory, which covers more than 57 municipalities within four counties in south-central Pennsylvania.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.